HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Borght, T. V. Articles by Laterre, C. Search for Related Content PubMed PubMed Citation Articles by Borght, T. V. Articles by Laterre, C.

Brain Tumor Imaging with PET and 2-[Carbon-11]Thymidine

Departments of Nuclear Medicine, Experimental Surgery, Positron Tomography Laboratory, Neurosurgery and Neurology, University of Louvain Medical School, Brussels, Belgium

Correspondence: For correspondence or reprints contact: Dr. Stanislas Pauwels, Centre de Médecine Nucléaire, UCL 54.30, Avenue Hippocrate 54, B-1200 Brussels Belgium, Belgium.

ABSTRACT

Methods: To assess the potential of thymidine for imaging brain tumors, 20 patients with untreated (n = 14) and recurrent (n = 6) supratentorial intracranial tumors were studied with PET by using 2-[¹¹C]thymidine (Tdr), and the results were compared with [¹⁸F]fluorodeoxyglucose (FDG) PET data. Results: Blood analysis consistently revealed a rapid clearance of the intact Tdr together with the appearance of CO₂/HCO₃^– that, with time, accounted for approximately 70% of the total blood activity. As soon as 10 min after tracer injection, brain images showed a low and homogeneous Tdr distribution over the normal brain structures (cortex-to-blood ratio approximately 1). Visual and quantitative analysis revealed increased Tdr uptake (tumor-to-cortex ratio 1.2) in 11 of 14 untreated tumors and in 5 of 6 recurrent tumors. No correlation was found between Tdr uptake and tumor grade. In 12 of the 14 untreated tumors, FDG uptake was low (tumor-to-cortex ratio: 0.83 ± 0.79), but a FDG hot spot was visualized in 8 of 10 high-grade and in none of the 4 low-grade tumors. FDG uptake was consistently low in recurrent tumors (tumor-to-cortex ratio:0.49 ± 0.19), and PET-FDG was negative in 3 of the 6 cases. Conclusion: These data indicate the feasibility of brain tumor imaging with Tdr and suggest the potential clinical usefulness of the method in the detection of tumor recurrences. The specificity of the method remains, however, to be investigated.

Key Words: 2-[carbon-11]thymidine • fluorine-18-fluorodeoxy-glucose • PET • brain tumors

This article has been cited by other articles:

				J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]

				D L Francis, A Freeman, D Visvikis, D C Costa, S K Luthra, M Novelli, I Taylor, and P J Ell In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography Gut, November 1, 2003; 52(11): 1602 - 1606. [Abstract] [Full Text] [PDF]

				L. Lu, L. Samuelsson, M. Bergstrom, K. Sato, K.-J. Fasth, and B. Langstrom Rat Studies Comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as Proliferation Markers J. Nucl. Med., December 1, 2002; 43(12): 1688 - 1698. [Abstract] [Full Text] [PDF]

				L. Lu, M. Bergstrom, K.-J. Fasth, and B. Langstrom Synthesis of [76Br]Bromofluorodeoxyuridine and Its Validation with Regard to Uptake, DNA Incorporation, and Excretion Modulation in Rats J. Nucl. Med., October 1, 2000; 41(10): 1746 - 1752. [Abstract] [Full Text] [PDF]

				R. G. Blasberg, U. Roelcke, R. Weinreich, B. Beattie, K. von Ammon, Y. Yonekawa, H. Landolt, I. Guenther, N. E. A. Crompton, P. Vontobel, et al. Imaging Brain Tumor Proliferative Activity with [124I]Iododeoxyuridine Cancer Res., February 1, 2000; 60(3): 624 - 635. [Abstract] [Full Text]